康缘药业(600557) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue for the period was CNY 1,078,976,001.36, representing an increase of 20.45% year-on-year[17]. - Net profit attributable to shareholders was CNY 111,669,956.27, an increase of 18.02% compared to the same period last year[17]. - Basic earnings per share were CNY 0.19, reflecting an increase of 18.75% compared to the previous year[17]. - Total operating revenue for Q1 2019 reached ¥1,078,976,001.36, a 20.4% increase from ¥895,793,447.02 in Q1 2018[47]. - Net profit for Q1 2019 was ¥112,268,257.95, up 18.0% from ¥95,086,207.00 in Q1 2018[48]. - Operating profit for Q1 2019 was ¥134,178,700.36, representing a 20.3% increase from ¥111,555,126.90 in Q1 2018[47]. - The total profit for Q1 2019 was ¥132,772,556.50, a 18.6% increase from ¥111,989,554.60 in Q1 2018[47]. - Earnings per share for Q1 2019 was ¥0.19, compared to ¥0.16 in Q1 2018, indicating a growth of 18.8%[48]. Cash Flow - Net cash flow from operating activities was CNY 117,860,065.30, down 39.70% year-on-year[17]. - The company's cash flow from operating activities decreased by 39.70% compared to the previous year, amounting to ¥117,860,065.30[28]. - The net cash flow from operating activities decreased to CNY 117.86 million in Q1 2019 from CNY 195.45 million in Q1 2018, a decline of about 39.6%[58]. - The cash inflow from operating activities was CNY 1.34 billion in Q1 2019, compared to CNY 1.22 billion in Q1 2018, marking an increase of approximately 9.5%[57]. - Total cash outflows for operating activities were CNY 1.22 billion in Q1 2019, compared to CNY 1.02 billion in Q1 2018, indicating an increase of approximately 19.5%[58]. - Cash inflows from financing activities increased significantly to CNY 800.99 million in Q1 2019, up from CNY 524.50 million in Q1 2018, representing a growth of approximately 52.7%[58]. - The net cash flow from financing activities improved to -CNY 103.04 million in Q1 2019, compared to -CNY 204.74 million in Q1 2018, showing a reduction in cash outflow by about 49.7%[58]. - The ending balance of cash and cash equivalents was CNY 267.65 million at the end of Q1 2019, compared to CNY 193.61 million at the end of Q1 2018, reflecting an increase of approximately 38.3%[58]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,513,315,333.63, a decrease of 1.60% compared to the end of the previous year[17]. - The total assets as of March 31, 2019, were ¥5,513,315,333.63, a decrease from ¥5,602,949,959.27 at the end of 2018[36]. - The company's total liabilities decreased to ¥1,514,396,056.38 from ¥1,574,914,147.10, reflecting a reduction of about 3.83%[42]. - Total current liabilities decreased to ¥1,440,302,345.83 from ¥1,498,064,582.55, reflecting a reduction of about 3.87%[42]. - Total current liabilities were CNY 1,613,275,844.74, while total liabilities amounted to CNY 1,710,721,112.39[70]. - Cash and cash equivalents decreased to ¥179,291,506.97 from ¥220,316,052.94, a decline of about 18.63%[39]. - Accounts receivable decreased to ¥1,949,043,815.96 from ¥2,022,034,190.00, representing a decrease of approximately 3.61%[39]. - The company's total equity attributable to shareholders was ¥3,672,306,741.50, down from ¥3,700,214,212.23, indicating a decrease of approximately 0.75%[43]. Shareholder Information - The total number of shareholders at the end of the reporting period was 28,182[21]. - Jiangsu Kangyuan Group Co., Ltd. held 28.58% of the shares, making it the largest shareholder[21]. Research and Development - Research and development expenses increased to ¥105,222,910.00 in Q1 2019, compared to ¥81,711,738.05 in Q1 2018, reflecting a growth of 28.7%[47]. Other Financial Metrics - The weighted average return on equity increased by 0.31 percentage points to 2.99%[17]. - The company reported a government subsidy of CNY 4,831,643.07 related to its normal business operations[17]. - The company executed new financial instrument standards starting January 1, 2019, impacting the reporting of financial assets[28]. - The company plans to use repurchased shares for cancellation to reduce registered capital, as approved in the board meeting[28].